Functional human corneal equivalents constructed from cell lines

Science

Volumn 286, Issue 5447, 1999, Pages 2169-2172

  Griffith, May ^a   Osborne, Rosemarie ^b   Hunger, Rejean ^a   Xiong, Xiaojuan ^c   Doillon, Charles J ^a   Laycock, Noelani L C ^a   Hakim, Malik ^d   Song, Ying ^a,b,c,d   Watsky, Mitchell A ^a,b,c,d  

^a UNIVERSITY OF OTTAWA EYE INSTITUTE   (Canada)

^b PROCTER AND GAMBLE COMPANY   (United States)

^c UNIVERSITY OF QUEBEC   (Canada)

^d UNIVERSITY OF TENNESSEE COLLEGE OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ARTICLE; CELL IMMORTALIZATION; CELL LINE; CELL STRUCTURE; CORNEA; CORNEA CELL; ELECTROPHYSIOLOGY; PRIORITY JOURNAL; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; TISSUE GRAFT;

ANIMAL TESTING ALTERNATIVES; BIOMEDICAL ENGINEERING; CELL LINE; CELLS, CULTURED; CHONDROITIN SULFATES; COLLAGEN; CORNEA; CORNEAL OPACITY; CORNEAL STROMA; CORNEAL TRANSPLANTATION; CROSS-LINKING REAGENTS; CULTURE TECHNIQUES; ELECTROPHYSIOLOGY; ENDOTHELIUM, CORNEAL; EPITHELIUM, CORNEAL; GENE EXPRESSION; GLUTARAL; HUMANS; ION CHANNELS; OUABAIN; PATCH-CLAMP TECHNIQUES; SODIUM DODECYL SULFATE;

EID: 0032797273     PISSN: 00368075     EISSN: None     Source Type: Journal    
DOI: 10.1126/science.286.5447.2169     Document Type: Article

References (46)

1. D. G. Pitts, in Environmental Vision, D. E. Pitts and R. N. Kleinstein, Eds. (Butterworth-Heinemann, Boston, 1994), chap. 6.
2. M. J. Jager et al., Eye 9, 241 (1995).
3. Y. Minami, H. Sugihara, S. Oono, Invest. Ophthalmol. Visual Sci. 34, 2316 (1993); J. D. Zieske et al., Exp. Cell Res. 214, 621 (1994); C. R. Kahn, E. Young I. H. Lee, J. S. Rhim, Invest. Ophthatmol. Visual Sci. 34, 1983 (1993); K. Araki-Sasaki et al., Invest. Ophthalmol. Visual Sci. 36, 614 (1995); L Germain et al., Pathobiology 67, 140 (1999).
4. Y. Minami, H. Sugihara, S. Oono, Invest. Ophthalmol. Visual Sci. 34, 2316 (1993); J. D. Zieske et al., Exp. Cell Res. 214, 621 (1994); C. R. Kahn, E. Young I. H. Lee, J. S. Rhim, Invest. Ophthatmol. Visual Sci. 34, 1983 (1993); K. Araki-Sasaki et al., Invest. Ophthalmol. Visual Sci. 36, 614 (1995); L Germain et al., Pathobiology 67, 140 (1999).
5. Y. Minami, H. Sugihara, S. Oono, Invest. Ophthalmol. Visual Sci. 34, 2316 (1993); J. D. Zieske et al., Exp. Cell Res. 214, 621 (1994); C. R. Kahn, E. Young I. H. Lee, J. S. Rhim, Invest. Ophthatmol. Visual Sci. 34, 1983 (1993); K. Araki-Sasaki et al., Invest. Ophthalmol. Visual Sci. 36, 614 (1995); L Germain et al., Pathobiology 67, 140 (1999).
6. Y. Minami, H. Sugihara, S. Oono, Invest. Ophthalmol. Visual Sci. 34, 2316 (1993); J. D. Zieske et al., Exp. Cell Res. 214, 621 (1994); C. R. Kahn, E. Young I. H. Lee, J. S. Rhim, Invest. Ophthatmol. Visual Sci. 34, 1983 (1993); K. Araki-Sasaki et al., Invest. Ophthalmol. Visual Sci. 36, 614 (1995); L Germain et al., Pathobiology 67, 140 (1999).
7. Y. Minami, H. Sugihara, S. Oono, Invest. Ophthalmol. Visual Sci. 34, 2316 (1993); J. D. Zieske et al., Exp. Cell Res. 214, 621 (1994); C. R. Kahn, E. Young I. H. Lee, J. S. Rhim, Invest. Ophthatmol. Visual Sci. 34, 1983 (1993); K. Araki-Sasaki et al., Invest. Ophthalmol. Visual Sci. 36, 614 (1995); L Germain et al., Pathobiology 67, 140 (1999).
8. "Immortalized cells" are cells with extended lifespans that retain characteristics of low-passage or freshly dissociated cells (contact inhibition, substrate-dependent growth, but no senescence or culture-related phenotypic changes after 8 to 10 passages).
9. C. L. Halbert, G. W. Demers, D. A. Galloway, J. Virol. 65, 473 (1991); J. Virol. 66, 2125 (1992). Viral producer cell line PA317LXSN 16E6E7 (American Type Culture Collection) was used.
10. C. L. Halbert, G. W. Demers, D. A. Galloway, J. Virol. 65, 473 (1991); J. Virol. 66, 2125 (1992). Viral producer cell line PA317LXSN 16E6E7 (American Type Culture Collection) was used.
11. J. S. Rhim et al., Carcinogenesis 19, 673 (1998).
12. R. E. Kingston, in Current Protocols Molecular Biology, F. M. Ausubel et al., Eds. ( Wiley, New York, 1997), pp. 9.0.1-9.1.11.
13. T. M. Bryan and R. R. Reddel, Crit. Rev. Oncog. 5, 331 (1994); P. J. Southern and P. Berg, J. Mol. Appl. Genet. 1, 327 (1982).
14. T. M. Bryan and R. R. Reddel, Crit. Rev. Oncog. 5, 331 (1994); P. J. Southern and P. Berg, J. Mol. Appl. Genet. 1, 327 (1982).
15. F. L. Graham and A. J. van der Eb, Virology 52, 456 (1973); M. P. Quinlan, Oncogene 9, 2639 (1994).
16. F. L. Graham and A. J. van der Eb, Virology 52, 456 (1973); M. P. Quinlan, Oncogene 9, 2639 (1994).
17. Cytogenetic analyses were performed by H. S. Wang (Cytogenetics Laboratory, Children's Hospital of Eastern Ontario, Ottawa) using routine G-banding techniques with 400-to 450-band resolution.
18. M. J. Pettenati et al., Hum. Genet. 101, 26 (1997).
19. TeloQuant Telomeric Repeat Amplification Protocol kit (Pharmingen Canada).
20. J. L. Rae, K. E. Cooper, P. Gates, M. A. Watsky, Br. J. Neurosci. Methods 37, 15 (1991).
21. C. Bockman, C. M. Griffith, M. A. Watsky, Invest. Ophthalmol. Visual Sci. 39, 1143 (1998).
22. Epithelial cells showed corneal epithelial-specific keratin 12 staining [A. Schermer, S. Galvin, T. T. Sun, J. Cell Biol. 103, 49 (1986)] with AE5 antibody (ICN Biochemicals, Aurora, OH). Stromal cells stained for vimentin (Roche Diagnostics, Montreal). Endothelial cells expressed α2(VIII) collagen mRNA [Y. Muragaki et al., J. Biol. Chem. 266, 7721 (1991)] and lacked keratin 12 staining.
23. Epithelial cells showed corneal epithelial-specific keratin 12 staining [A. Schermer, S. Galvin, T. T. Sun, J. Cell Biol. 103, 49 (1986)] with AE5 antibody (ICN Biochemicals, Aurora, OH). Stromal cells stained for vimentin (Roche Diagnostics, Montreal). Endothelial cells expressed α2(VIII) collagen mRNA [Y. Muragaki et al., J. Biol. Chem. 266, 7721 (1991)] and lacked keratin 12 staining.
24. E. Bell, H. P. Ehrlich, D. J. Buttle, T. Nakatsuji, Science 211, 1052 (1981); M. S. Shoichet and J. A. Hubell, Eds., Polymers for Tissue Engineering (VSP, Utrecht, Netherlands, 1998).
25. E. Bell, H. P. Ehrlich, D. J. Buttle, T. Nakatsuji, Science 211, 1052 (1981); M. S. Shoichet and J. A. Hubell, Eds., Polymers for Tissue Engineering (VSP, Utrecht, Netherlands, 1998).
26. Cell lines producing successful constructs were from young donors, were immortalized with HPV E6/E7, and had appropriate electrophysiological responses.
27. M. Griffith et al., in preparation.
28. W. W. Y. Kao, R. A. Berg, D. J. Prockop, Biochim. Biophys. Acta 411, 202 (1975); C. J. Doillon, F. H. Silver, R. A. Berg, Biomaterials 8, 195 (1987).
29. W. W. Y. Kao, R. A. Berg, D. J. Prockop, Biochim. Biophys. Acta 411, 202 (1975); C. J. Doillon, F. H. Silver, R. A. Berg, Biomaterials 8, 195 (1987).
30. M. Griffith et al., unpublished data.
31. R. Janvier, A. Sourla, M. Koutsilieris, C. J. Doillon, Anticancer Res. 17, 1551 (1997).
32. M. A. Watsky, T. W. Olsen, H. F. Edethauser, in Duane's Foundations of Clinical Ophthalmology, B. Tasman and E. Jaeger, Eds. (Lippincott, Philadelphia, 1995), vol. 2, chap. 4.
33. D. H. Geroski, J. C. Kies, and H. F. Edelhauser [Curr. Eye Res. 3, 331 (1984)] showed that 100 μM ouabain causes swelling of human corneas (41 μm per hour); after 2 hours corneas would swell by 82 μm (16%).
34. Constructs, with epithelium sealed with silicone oil to prevent movement of water across the anterior surface, were measured using OCT (Zeiss-Humphrey, San Leandro, CA). The average change in thickness was calculated from four to six measurements before and after treatment of the endothelial surface for 2 hours with 100 μM ouabain or Dulbecco's modified Eagle's medium alone (DMEM, Gibco).
35. 32P]deoxycytidine triphosphate-labeled specific probes. Quantification was performed on a Molecular Dynamics Storm Phosphorimager.
36. J. H. Draize, G. Woodard, H. O. Calvery, J. Pharmacol. Exp. Ther. 82, 377 (1944); J. F. Griffith, G. A. Nixon, R. D. Bruce, P. J. Reer, E. A. Bannan, Toxicol. Appl. Pharmacol. 55, 501 (1980).
37. J. H. Draize, G. Woodard, H. O. Calvery, J. Pharmacol. Exp. Ther. 82, 377 (1944); J. F. Griffith, G. A. Nixon, R. D. Bruce, P. J. Reer, E. A. Bannan, Toxicol. Appl. Pharmacol. 55, 501 (1980).
38. c-fos: Y. Okada et al., Graefes Arch. Clin. Exp. Ophthalmol. 236, 853 (1998); IL-1 and IL-6: C. Sotozono et al., Curr. Eye Res. 16, 670 (1997); bFGF; V. P. T. Hoppenreijs, E. Pels, G. F. J. M. Vrensen, W. F. Treffers, Invest. Ophthalmol. Visual Sci. 35, 931 (1994); VEGF: S. Amano, R. Roban, M. Kuroki, M. Tolentino, A. P. Adamis, Invest. Ophthalmol. Visual Sci. 39, 18 (1998); Coll I: W. J. Power, A. H. Kaufman, J. Merayo-Lloves, V. Arrunategui-Correa, C. S. Foster, Curr. Eye Res. 14, 879 (1995).
39. c-fos: Y. Okada et al., Graefes Arch. Clin. Exp. Ophthalmol. 236, 853 (1998); IL-1 and IL-6: C. Sotozono et al., Curr. Eye Res. 16, 670 (1997); bFGF; V. P. T. Hoppenreijs, E. Pels, G. F. J. M. Vrensen, W. F. Treffers, Invest. Ophthalmol. Visual Sci. 35, 931 (1994); VEGF: S. Amano, R. Roban, M. Kuroki, M. Tolentino, A. P. Adamis, Invest. Ophthalmol. Visual Sci. 39, 18 (1998); Coll I: W. J. Power, A. H. Kaufman, J. Merayo-Lloves, V. Arrunategui-Correa, C. S. Foster, Curr. Eye Res. 14, 879 (1995).
40. c-fos: Y. Okada et al., Graefes Arch. Clin. Exp. Ophthalmol. 236, 853 (1998); IL-1 and IL-6: C. Sotozono et al., Curr. Eye Res. 16, 670 (1997); bFGF; V. P. T. Hoppenreijs, E. Pels, G. F. J. M. Vrensen, W. F. Treffers, Invest. Ophthalmol. Visual Sci. 35, 931 (1994); VEGF: S. Amano, R. Roban, M. Kuroki, M. Tolentino, A. P. Adamis, Invest. Ophthalmol. Visual Sci. 39, 18 (1998); Coll I: W. J. Power, A. H. Kaufman, J. Merayo-Lloves, V. Arrunategui-Correa, C. S. Foster, Curr. Eye Res. 14, 879 (1995).
41. c-fos: Y. Okada et al., Graefes Arch. Clin. Exp. Ophthalmol. 236, 853 (1998); IL-1 and IL-6: C. Sotozono et al., Curr. Eye Res. 16, 670 (1997); bFGF; V. P. T. Hoppenreijs, E. Pels, G. F. J. M. Vrensen, W. F. Treffers, Invest. Ophthalmol. Visual Sci. 35, 931 (1994); VEGF: S. Amano, R. Roban, M. Kuroki, M. Tolentino, A. P. Adamis, Invest. Ophthalmol. Visual Sci. 39, 18 (1998); Coll I: W. J. Power, A. H. Kaufman, J. Merayo-Lloves, V. Arrunategui-Correa, C. S. Foster, Curr. Eye Res. 14, 879 (1995).
42. c-fos: Y. Okada et al., Graefes Arch. Clin. Exp. Ophthalmol. 236, 853 (1998); IL-1 and IL-6: C. Sotozono et al., Curr. Eye Res. 16, 670 (1997); bFGF; V. P. T. Hoppenreijs, E. Pels, G. F. J. M. Vrensen, W. F. Treffers, Invest. Ophthalmol. Visual Sci. 35, 931 (1994); VEGF: S. Amano, R. Roban, M. Kuroki, M. Tolentino, A. P. Adamis, Invest. Ophthalmol. Visual Sci. 39, 18 (1998); Coll I: W. J. Power, A. H. Kaufman, J. Merayo-Lloves, V. Arrunategui-Correa, C. S. Foster, Curr. Eye Res. 14, 879 (1995).
43. Live/Dead Viability/Cytotoxicity kit (Molecular Probes, Eugene, OR).
44. 2] × 100, and compared within and across species using analysts of variance (ANOVA).
45. International Life Sciences Institute, J. Toxicol. Cutaneous Ocul. Toxicol. 15, 211 (1996).
46. Supported by grants from the Natural Sciences and Engineering Research Council of Canada, Medical Research Council-Pharmaceutical Manufacturers' Association of Canada, and the P&G International Program for Animal Alternatives. We thank S. Whelan and P. Berg for AdS and psvBneo plasmids, C. Smith and Ottawa Hospital Research Institute colleagues, and E. Hay and A. Tashjian Jr. for helpful insights during preparation of this manuscript.